NO974726L - Glucose-induktibel, rekombinant, viral vektor - Google Patents

Glucose-induktibel, rekombinant, viral vektor

Info

Publication number
NO974726L
NO974726L NO974726A NO974726A NO974726L NO 974726 L NO974726 L NO 974726L NO 974726 A NO974726 A NO 974726A NO 974726 A NO974726 A NO 974726A NO 974726 L NO974726 L NO 974726L
Authority
NO
Norway
Prior art keywords
inducible
recombinant
glucose
viral vector
viral
Prior art date
Application number
NO974726A
Other languages
English (en)
Other versions
NO974726D0 (no
Inventor
Ruihuan Chen
Bruno Doiron
Axel Kahn
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO974726D0 publication Critical patent/NO974726D0/no
Publication of NO974726L publication Critical patent/NO974726L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO974726A 1995-04-14 1997-10-13 Glucose-induktibel, rekombinant, viral vektor NO974726L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504558A FR2732978B1 (fr) 1995-04-14 1995-04-14 Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
PCT/FR1996/000560 WO1996032489A1 (fr) 1995-04-14 1996-04-12 Vecteur viral recombinant inductible par le glucose

Publications (2)

Publication Number Publication Date
NO974726D0 NO974726D0 (no) 1997-10-13
NO974726L true NO974726L (no) 1997-10-13

Family

ID=9478162

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974726A NO974726L (no) 1995-04-14 1997-10-13 Glucose-induktibel, rekombinant, viral vektor

Country Status (14)

Country Link
US (1) US6309878B1 (no)
EP (1) EP0821741A1 (no)
JP (1) JPH11503608A (no)
KR (1) KR19980703843A (no)
AU (1) AU715377B2 (no)
BR (1) BR9604938A (no)
CA (1) CA2215987A1 (no)
CZ (1) CZ292564B6 (no)
FR (1) FR2732978B1 (no)
HU (1) HUP9802587A3 (no)
MX (1) MX9707910A (no)
NO (1) NO974726L (no)
SK (1) SK137797A3 (no)
WO (1) WO1996032489A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5257198A (en) * 1996-11-15 1998-06-03 Millennium Pharmaceuticals, Inc. Compositions and methods for treating type ii diabetes involving hnf-4
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US6503887B1 (en) 1999-02-19 2003-01-07 Matthew During Peroral gene therapy of diabetes and obesity
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
JP3406244B2 (ja) 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
EP1199720A4 (en) 1999-05-27 2008-01-23 Hitachi Global Storage Tech TURNTABLE
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
DE102005024884A1 (de) * 2005-05-31 2006-12-07 Linde Ag Arbeitsmaschine, insbesondere Flurförderzeug
US20070020237A1 (en) * 2005-06-01 2007-01-25 Biotech Institute For International Innovation, Inc. Glucose inducible insulin expression and methods of treating diabetes
ES2325711B1 (es) * 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007392A (en) * 1991-05-29 1993-01-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Eukaryotic expression vectors with regulation of rna processing
JP3534749B2 (ja) * 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
AU687836B2 (en) * 1993-06-28 1998-03-05 Board Of Regents, The University Of Texas System Vectors for genetically engineered cells that produce insulin in response to glucose

Also Published As

Publication number Publication date
BR9604938A (pt) 1998-06-09
KR19980703843A (ko) 1998-12-05
AU715377B2 (en) 2000-02-03
CZ325197A3 (cs) 1998-01-14
SK137797A3 (en) 1998-05-06
CA2215987A1 (fr) 1996-10-17
FR2732978B1 (fr) 1997-05-30
MX9707910A (es) 1997-11-29
JPH11503608A (ja) 1999-03-30
EP0821741A1 (fr) 1998-02-04
CZ292564B6 (cs) 2003-10-15
NO974726D0 (no) 1997-10-13
HUP9802587A3 (en) 1999-12-28
FR2732978A1 (fr) 1996-10-18
WO1996032489A1 (fr) 1996-10-17
HUP9802587A2 (hu) 1999-02-01
US6309878B1 (en) 2001-10-30
AU5652396A (en) 1996-10-30

Similar Documents

Publication Publication Date Title
AU2678097A (en) Targeted viral vectors
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
AU3119895A (en) Recombinant virus vectors
DE69420033D1 (de) Gibbon leukemia virus retrovirale vektoren
NO974562L (no) Antifugale, cykliske peptider
DE69926557D1 (de) Reduziertes Vektor Raster
HUP9801266A3 (en) Multimeric, recombinant urease vaccine
ATE348169T1 (de) Selektiv-replizierende virale vectoren
TR199500915A2 (tr) Peptidler.
NO974726D0 (no) Glucose-induktibel, rekombinant, viral vektor
FI970081A7 (fi) Dinukleosidi-5',5'-pyrofosfaatit
AU2344100A (en) Viral vectors with late transgene expression
FI933980A0 (fi) Skyddsplagg foer hygienkraevande objekt, saosom operationssalar
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
FR11C0050I2 (fr) Virus myxomateux recombinant
EP0649471A4 (en) Recombinant cellulases.
BR9605220B1 (pt) gonadotropinas recombinantes.
FI924395L (fi) Icke-a, icke-b-peptider
ES1032571Y (es) Gafa,
GB9501300D0 (en) Peptides which inhibit viruses
FI930961A0 (fi) Matstation foer koettboskap, saerskilt svin
HK1001658A (en) Recombinant virus vectors
GB9304962D0 (en) Recombinant virus
GB9825053D0 (en) Recombinant virus
NO944177D0 (no) Styrt, flervinge - gjennomgangsdör

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application